Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazil
- PDF / 436,418 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 203 Views
ORIGINAL RESEARCH
Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System Greta Lozano-Ortega
. Daniel B. Ng . Shelagh M. Szabo
.
Alison M. Deighton . Bruno Riveros . Anne Guttschow . Katherine L. Gooch . Cristiano M. Gomes
Received: October 28, 2019 Ó The Author(s) 2020
ABSTRACT Introduction: In Brazil, current data on the use of healthcare resources to manage individuals with overactive bladder (OAB) are lacking. This study aimed to characterize contemporary treatment and the economic burden among patients with OAB managed under the Brazilian ´ nico de Sau´de public health system (Sistema U [SUS]). Methods: Population-based data from January to December of 2015 were acquired from Brazil’s Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12026232. Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01318-w) contains supplementary material, which is available to authorized users. G. Lozano-Ortega S. M. Szabo A. M. Deighton Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canada D. B. Ng (&) A. Guttschow K. L. Gooch Astellas Pharma Global Development, Inc., Northbrook, IL, USA e-mail: [email protected] B. Riveros MAPESolutions, Sao Paulo, Brazil C. M. Gomes Division of Urology, Department of Surgery, University of Sao Paulo-Sao Paulo/SP School of Medicine, Sao Paulo, Brazil
public health database. Adults at least 18 years of age with an ICD-10 diagnostic code for OAB within the period were included. Records of outpatient visits, hospitalizations, and onabotulinumtoxinA injections were used to calculate estimates of resource use and costs (in Brazilian reals [R$]) among those with OAB (frequency [%] and mean (standard deviation [SD]) as appropriate). Patient identifiers were not available, so a record linkage methodology was used to match medical encounters to individuals. Pharmacologic management of OAB was informed by government medication purchases available from the official Brazilian government databases. Results: During 2015, 26,640 patients with OAB were identified. All cohort members had at least one outpatient visit and 15,349 (57.6%) were hospitalized. Of the study cohort, 10.0% visited a general practitioner (GP), 41.3% visited a specialist, and 52.0% visited other non-medical healthcare practitioners within the year. Mean (SD) healthcare costs among the study cohort totaled R$355 (R$866) per patient per year; and were R$291 (R$654), R$27 (R$130), R$27 (R$30), and R$11 (R$17) for hospitalizations, GP, specialist, and non-medical healthcare practitioner visits per patient per year, respectively. Regional analysis of reported government medication purchases suggested that access to OAB treatments is highly limited. Conclusions: High resource use and costs were estimated among patients with OAB managed
Adv Ther
within the SUS. These data provide a snapshot of the management of pa
Data Loading...
